Zheng Quan Shi Bao Wang·2025-08-19 00:05Core Viewpoint - Rongchang Biopharmaceutical (688331) has entered into an agreement with Santen Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Santen (China) Co., Ltd., to license its proprietary RC28-E injection for a fee, granting Santen exclusive rights for development, production, and commercialization in Greater China and several Southeast Asian countries [1] Financial Summary - Rongchang Biopharmaceutical will receive a non-refundable and non-offsettable upfront payment of 250 million RMB from Santen China [1] - The agreement includes potential milestone payments of up to 520 million RMB for development and regulatory achievements, and up to 525 million RMB for sales milestones [1] - Additionally, Rongchang will earn a tiered sales royalty based on product sales in the licensed regions, ranging from high single-digit to double-digit percentages [1] Product Information - RC28-E injection is a dual-target fusion protein drug developed by Rongchang Biopharmaceutical, aimed at treating ocular neovascular diseases [1]